Marginal Benefits in High-Risk Ovarian Cancer With Addition of Bevacizumab to Chemo

(MedPage Today) -- Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab (Avastin) to first-line chemotherapy, while patients without high risk did not benefit, a large real-world...